Two-year outcome of intravitreal bevacizumab for myopic choroidal neovascularization

Purpose: To report the outcome during 2 years after intravitreal injection of bevacizumab for choroidal neovascularization in myopic eyes. Cases: This retrospective study was made on 38 eyes of 37 patients who received intravitreal injection of bevacizumab for myopic choroidal neovascularization. The series comprised 31 females and 6 males. The age ranged from 39 to 80 years, average 60 years. Refraction ranged from -6.3 to -20.5 diopters, average -11.5 diopters. Visual acuity was evaluated in terms of logMAR. Results: Visual acuity averaged 0.61±0.42 before treatment. It averaged 0.39±0.31 after 3 months, 0.35 ±0.27 after 6 months, and 0.45 ±0.36 after 2 years. All the values were significant when compared with the value before treatment (p<0.05). The treatment was repeated 2.1 ±1.4 times when averaged for each eye during the period of 2 years. Multiple regression analysis showed visual acuity before treatment, age of patient and location of CNV as significant factors related with the visual outcome. Conclusion: Intravitreal injection of bevacizumab resulted in significantly improved visual acuity in eyes with myopic CNV.